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Abstract  
Ligands addressed to the mitochondrial Translocator Protein (TSPO) have been suggested as cell 
death/life and steroidogenesis modulators. Thus, TSPO ligands have been proposed as drug 
candidates in several diseases; nevertheless, a correlation between their binding affinity and in vitro 
efficacy has not been demonstrated yet, questioning the specificity of the observed effects. Since 
drug-target residence time is an emerging parameter able to influence drug pharmacological 
features, herein, the interaction between TSPO and irDE-MPIGA, a covalent TSPO ligand, was 
investigated in order to explore TSPO control on death/life processes in a standardized glioblastoma 
cell setting. After 90 min irDE-MPIGA cell treatment, 25 nM ligand concentration saturated 
irreversibly all TSPO binding sites; after 24 h, TSPO de-novo synthesis occurred and about 40% 
TSPO binding sites resulted covalently bound to irDE-MPIGA. During cell culture treatments, 
several dynamic events were observed: a) early apoptotic markers appeared, such as mitochondrial 
membrane potential collapse (at 3 h) and externalization of phosphatidylserine (at 6 h); b) cell 
viability was reduced (at 6 h), without cell cycle arrest. After digitonin-permeabilized cell 
suspension treatment, a modulation of mitochondrial permeability transition pore was evidenced. 
Similar effects were elicited by the reversible TSPO ligand PIGA only when applied at micromolar 
dose. Interestingly, after 6 h, irDE-MPIGA cell exposure restored cell survival parameters. These 
results highlighted the ligand-target residence time and the cellular setting are crucial parameters 
that should be taken into account to understand the drug binding affinity and efficacy correlation 
and, above all, to translate efficiently cellular drug responses from bench to bedside. 
 
Keywords: Translocator Protein (18 kDa); irreversible TSPO ligand; residence time; apoptosis; 
U87MG cells; mitochondrial membrane permeability transition (MPT) pore. 
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Introduction 
TSPO has been proposed to play a key role in critical cell processes such as cell death/survival, 
differentiation, heme synthesis, porphyrin transport, regulation of mitochondrial function, and 
steroidogenesis [1]. Although TSPO expression is particularly abundant in steroid/neurosteroid 
producing cells, it has been found in every tissue examined, showing abnormal levels in different 
pathological conditions, particularly in cancer and neuroinflammation [1, 2]. All these features have 
led to propose TSPO as a promising pharmacological target and a strategic diagnostic tool. Several 
synthetic ligands with nanomolar/subnanomolar binding affinity to TSPO have been developed [3] 
and some of these are under investigation in Alzheimer’s disease [4], multiple sclerosis [5], 
neurotrauma [6], neuroinflammation [7], anxiety disorders [8], cardiovascular diseases [9], and 
cancer [10]. Clinical trials for some TSPO ligands are concluded (Clinical Trials.gov Identifier: 
NCT00108836) or are currently recruiting participants (NCT01547780), and the marketed 
Etifoxine, a TSPO ligand, is already clinically approved for the treatment of anxiety-related 
disorders (Stresam®, Biocodex, Gentilly, France). Concerning the results obtained by the closed 
Phase II study (NCT00108836), the TSPO ligand XBD173 (AC-5316, Emapunil) has shown a 
mean reduction, compared with placebo, in anxiety from baseline to week 6 in patients with 
generalized anxiety disorder. 
Ligands for TSPO have shown both pro-survival and antiproliferative/pro-apoptotic activities, or 
can act as chemo-sensitizers [11-31]. Classic TSPO ligands have been demonstrated to stimulate 
cell proliferation [11-13], to protect against apoptosis [14-16] and to facilitate apoptosis [17-30]. 
However, the effects of these TSPO ligands on cell death/life mechanisms may vary depending on 
the ligand concentration, the experimental setting and the type of cell populations. Interestingly, 
when used at micromolar concentration in several pharmacological studies, a lack of correlation 
between the binding affinity of a TSPO ligand and its in vitro effective dose has emerged [17-30, 
32-36]. This discrepancy has often questioned the specificity of the observed effects. Recent studies 
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have shown that the affinity of a ligand for its target could not directly define its biological action 
effectiveness that it may instead be related to the ‘drug-target residence time’ [37]. In support, a 
retrospective assessment of successfully launched drugs has revealed that their favorable effects in 
patients may be attributed to long lifetime of the binary drug-target complex [38]. 
All together, these evidences prompted us to investigate the effects caused by a stable occupancy of 
the TSPO binding sites. For this purpose, nanomolar doses of irDE-MPIGA, a synthetic ligand that 
covalently binds TSPO [39] (Fig. 1A), were used at different times. Specifically, in this paper our 
attention was focused on checking irDE-MPIGA effects in cell death/life processes in a cancer in 
vitro model (U87MG cells), comparing the results with those obtained using PIGA, a reversible 
TSPO ligand [40]. In the complex scenario of TSPO ligand death/life modulation, the obtained data 
confirmed the pharmacological profiles of drugs depend on their concentrations and demonstrated a 
correlation between ligand effective dose and residence time. Cellular setting standardization was 
demonstrated useful to obtain indication about the compensatory cell mechanisms and the final 
response to the drug. 
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Materials and Methods 
 
Materials 
 
The TSPO ligands irDE-MPIGA and PIGA were synthesized essentially as previously reported [39, 
40]. The low passage number human U87MG GBM cell line was obtained from the National 
Institute for Cancer Research of Genoa (Italy) and monitored for DNA profiling. [
3
H]PK11195 
(Specific Activity 84.8 Ci/mmol) was obtained from Perkin-Elmer Life Sciences. Carbonylcyanide-
m-chlorophenylhydrazone (CCCP), Nonidet P-40 (NP-40), cyclosporin A (CsA), oligomycin and 
PK11195 were obtained from Sigma–Aldrich, Milano, Italy. Fluorescent dyes, 5,50,6,60-
tetrachloro-1,10,3,30-tetraethylbenzimidazolcarbocyanine iodide (JC-1) and Calcium-Green-5N, 
were obtained from Molecular Probes, Invitrogen, Milano, Italy. The 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay kit was from Promega 
Italia, Milano, Italy. The RNeasy® Mini Kit was from Qiagen, Milano, Italy and the ProtoScript® 
cDNA Synthesis Kit was obtained from Biolabs, Euroclone, Milano, Italy. The Muse Annexin V 
and Dead Cell Kit and the Muse cell cycle kit were from Merck KGaA, Darmstadt, Germany. The 
ATP synthase specific activity microplate assay kit ab109716 was from Abcam, UK. TSPO 
polyclonal primary antibody (FL-169) sc-20120, TSPO siRNA (human) sc-40821, siRNA dilution 
buffer sc-29527, siRNA transfection reagent sc-2058, siRNA transfection medium sc-36868 and 
control siRNA-A sc-37007 were form Santa Cruz Biotechnology (Santa Cruz, CA). All other 
chemicals were obtained from standard commercial sources. 
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Experimental setting  
 
U87MG cells: quantification of TSPO binding sites by [
3
H]PK11195 binding assays. A growing 
body of literature demonstrates that the passage number affects cell line’s characteristics, such as 
the responses to stimuli [41,42]. Thus, U87MG cells at low passage numbers were used for all 
analyses. The U87MG cells were cultured in RPMI medium supplemented with 10% FBS, 2 mM L-
glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin and 1% non-essential amino acids at 
37°C in 5% CO2. The TSPO expression levels in U87MG cells were quantified by radioligand 
binding assays using [
3
H]PK11195, as previously described [43]. Briefly, aliquots of U87MG cell 
membranes (20 µg of proteins) were incubated in triplicates with increasing [
3
H]PK11195 
concentrations (0.5-20 nM) in the presence or the absence of unlabeled 1 µM PK11195, in the final 
volume of 500 µl of assay buffer for 90 min at 0°C. The ethanol concentration in the incubation 
buffer was less than 1% and did not interfere with specific [
3
H]PK11195 binding. Samples were 
rapidly filtered under vacuum through GF/C glass fiber filters. After being washed four times with 3 
ml of assay buffer, radioactivity trapped on the filter was measured by liquid scintillation counter 
(TopCount; PerkinElmer Life and Analytical Sciences; 65% counting efficiency). In U87MG cell 
membranes, [
3
H]PK11195 maximum number of binding sites (Bmax) and affinity (Kd) were 
determined by Scatchard analysis of saturation binding data. Saturation data were fitted using Prism 
software (version 3.0; GraphPad Software Inc., San Diego, CA).  
U87MG cells: drug treatments. The U87MG cells were seeded and after 24 h, the culture medium 
was replaced with fresh medium containing irDE-MPIGA (solubilized in DMSO) or DMSO 
(control sample). The DMSO did not exceed 1% (v/v). The quantification of Bmax value allowed 
calculating the irDE-MPIGA dose useful to saturate TSPO binding sites and to use for U87MG cell 
treatments. For each experiment, a single irDE-MPIGA dose (1.25 x 10
-3
 nmol/1x10
6
 cells) was 
applied to U87MG cell cultures and specific effects exerted by the compound were monitored at 
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indicated time points up to 24 h treatment. In parallel, the U87MG cells were treated with the 
reversible TSPO ligand PIGA. 
U87MG cells: irDE-MPIGA-TSPO stable interaction determination. irDE-MPIGA- or DMSO-
treated U87MG cell membranes (20 mg) were incubated with a single [
3
H]PK11195 concentration 
(4 nM) for 90 min at 0°C. Non-specific [
3
H]PK11195 binding was determined in the presence of    
1 mM PK11195. After incubation time, the samples were processed as above reported. 
U87MG cells after treatment: TSPO expression levels determination. Following U87MG cell 
treatment with irDE-MPIGA, the relative quantification of TSPO mRNA and protein were 
performed by real-time reverse transcription polymerase chain reaction (real-time RT-PCR) and 
Western blot analysis, respectively, as previously described [44, 45]. 
For real-time RT-PCR analysis, total RNA was isolated from DMSO- or irDE-MPIGA-treated 
U87MG cells using the RNeasy® Mini Kit. The purity of the RNA samples was determined by 
measuring the absorbance at 260:280 nm. cDNA synthesis was performed with 500 ng of RNA 
using the Quantitect® reverse transcriptase kit. The primers used for the RT-PCR were designed to 
span intron/exon boundaries to ensure that products did not include genomic DNA. The nucleotide 
sequences of primers were: FOR- 5’-CTG GGG CAC GCT CTA CTC-3’; REV 5’-CAG CAG 
GAG CTC CAC CAA G-3’. The RT-PCR reactions consisted of 12.5 mL of Brilliant® II SYBR® 
Green premix, 2.5 mL of both the forward and reverse primers (300 nM), 3 mL of cDNA and 4.5 mL 
of H2O. All reactions were performed for 40 cycles using the following temperature profiles: 98 °C 
for 30 seconds; 55 °C for 30 seconds and 72 °C for 3 seconds. β-actin was used as the housekeeping 
gene. The primers for β-actin mRNA amplification were: FOR: 5’-GCA CTC TTC CAG CCT TCC 
TTC C-3’; REV-5’-GAG CCG CCG ATC CAC ACG-3’. PCR specificity was determined using 
both a melting curve analysis and gel electrophoresis, and the data were analyzed by the standard 
curve method. TSPO mRNA levels for each sample were normalized against β-actin mRNA levels, 
and relative expression was calculated using the Ct value. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
8 
 
For Western blot analysis, the 24 h DMSO- or irDE-MPIGA-treated U87MG cells were lysed for 
60 min at 4 °C by adding RIPA buffer (9.1 mM NaH2PO4, 1.7 mM Na2HPO4, 150 mM NaCl, pH 
7.4, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS and a protease inhibitor cocktail). 
Cell extracts (50 µg) were diluted in Laemmli solution, resolved by SDS-PAGE (8.5%), transferred 
to PVDF membranes and probed overnight at 4 °C with a primary anti-TSPO antibody (1:200 (FL-
169): sc-20120; epitope corresponding to amino acids 1-169, representing TSPO full length of 
human origin). The primary antibody was detected using anti-rabbit IgG light chains conjugated to 
peroxidase (diluted 1:10,000). The peroxidase was detected using a chemoluminescent substrate 
(ECL, Perkin Elmer). 
 
U87MG cells after treatment: survival analysis 
 
Cell survival analysis was determined by conventional viability assays [46]. Specifically, cell 
number was determined using Trypan blue dye exclusion assay and Scepter 2.0 Automated Cell 
Counter (Millipore) as previously described [47]. The colorimetric assay utilizing MTS reagent was 
used to establish the PIGA concentration that inhibited 50% (IC50 value) of U87MG cell survival 
after 24 h of treatment and was performed according to the manufacturer’s instructions. Sigmoidal 
dose-response curves were generated using GraphPad Prism 4 software (GraphPad Software Inc., 
San Diego, CA), from which the IC50 value was derived. 
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U87MG cells: irDE-MPIGA specific effect determination 
 
To investigate the specificity of the irDE-MPIGA-induced effects in U87MG cells, cell survival 
analysis was performed in U87MG cells transfected with a siRNA specifically designed for the 
silencing of the human TSPO (sc-40821, Santa Cruz Biotechnology). The siRNA was transfected 
with siRNA transfection reagent (sc-29528) to a final concentration of 50 nM, following the 
manufacturer's protocol. In parallel to each silencing experiment, an ineffective sequence of RNA 
was used as negative control (sc-37007). Transfected U87MG cells were used 48 and 72 h after 
siRNA transfection. The silence efficacy was verified by [
3
H]PK11195 binding assays. Specifically, 
U87MG cell membrane homogenates (20 mg) were incubated with [
3
H]PK11195 (6 nM) for 90 min 
at 0°C in the final volume of 500 µl of assay buffer. Non-specific [
3
H]PK11195 binding was 
determined in the presence of 1 mM PK11195. After incubation time, the samples were processed as 
above reported. For cell survival analysis, transfected U87MG cells were treated with DMSO or a 
nanomolar dose of irDE-MPIGA (1.25 x 10
-3
 nmol/1x10
6
 cells) for 6 h and the viable and dead cells 
were determined by Trypan blue dye exclusion assay. 
To explore if irDE-MPIGA affected the activity of ATP synthase, the activity and quantity of ATP 
synthase derived by U87MG cells were analyzed using a multiplexing microplate kit (ab109716, 
Abcam, UK), according to the manufacturer’s instructions. Briefly, the supplied detergent (10 % 
v/v) was added to the thawed U87MG cell homogenates (5 mg/ml) for obtaining solubilization of 
intact ATP synthase. Then, ATP synthase was immunocaptured within the wells (50 mg 
protein/well) of the microplate and the enzyme activity measured by monitoring the rate of decrease 
in absorbance at 340 nm over time. Subsequently, in these same wells, the quantity of ATP synthase 
was determined by adding an ATP synthase specific antibody conjugated with alkaline phosphatase. 
The enzyme quantity was monitored as the change in absorbance at 405 nm over time. The 
sensitivity of the assay was monitored by the use of 100 nM oligomycin. To evaluate if TSPO 
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ligand affected ATP synthase activity, the relative ATP synthase specific activity was compared 
between TSPO ligand-treated and control sample. In parallel, the classic TSPO ligand PK11195 
was used as reference TSPO ligand at 2.5 mM and 250 mM.  
 
U87MG cells after treatment: Cell cycle analysis  
 
The measurement of the percentage of cells in the G0/G1, S, and G2/M phases of cell cycle was 
performed using the Muse™ Cell Analyzer (Muse™ Cell Analyzer, Merck KGaA, Darmstadt, 
Germany). Briefly, treated U87MG cells were collected and centrifuged at 300 x g for 5 minutes. 
After washing with 1X PBS, cells were fixed, slowly adding 1 mL of ice cold 70% ethanol and 
maintaining o/n at –20°C. Then, a cell suspension aliquot (containing at least 2 x 10
5
 cells) was 
centrifuged at 300 x g for 5 minutes, washed once with 1X PBS and suspended in the fluorescent 
reagent (Muse™ Cell Cycle reagent). After incubation for 30 min, the measurements of the 
percentage of cells in the phases of cell cycle were acquired. 
 
U87MG cells after treatment: mitochondrial potential change analysis 
 
Changes in mitochondrial potential (ΔΨm) were assessed using the fluorescent dye JC-1, which has 
been considered a reliable and sensitive fluorescent probe for detecting differences in ΔΨm [48, 
49]. JC-1 distributes first into cytoplasm (emitting green fluorescence) and then it is taken into 
mitochondria, where it forms aggregates (showing orange/red fluorescence) [50]. It has been 
established that JC1 accumulates within mitochondria in inverse proportion to ΔΨ according to the 
Nernst equation [50] and a reduction of JC-1 orange/red fluorescence is an index of ΔΨ dissipation 
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[51-53]. The ΔΨm of treated U87MG cells was determined by labeling both floating and adherent 
cells with JC-1 for 20 min at room temperature, as previously described [24, 43]. The orange/red 
JC-1 aggregate fluorescence was recorded by flow cytometry in the fluorescence channel 2 (FL-2) 
and green JC-1 monomer fluorescence in the fluorescence channel 1 (FL-1). Necrotic fragments 
were electronically gated out, on the basis of morphological characteristics on the forward light 
scatter versus side light scatter dot plot. As positive control, an aliquot of U87MG cells was 
incubated in the presence of the uncoupling agent CCCP. 
 
U87MG cells after treatment: annexin V/7-AAD staining analysis 
 
The cell apoptosis was measured using Annexin V coniugated to fluorescein-isothiocyanate (FITC) 
and 7-amino-actinomysin (7-AAD) dual staining. Briefly, the treated U87MG cells (both floating 
and adherent cells) were collected and subjected to Annexin V-FITC and 7-AAD staining. Muse™ 
Cell Analyzer measured the sample fluorescence of 10,000 cells. In cells undergoing apoptosis, 
Annexin V bound to phosphatidylserine, which translocated from the inner to the outer leaflet of the 
cytoplasmic membrane. Double staining was used to distinguish between viable, early apoptotic, or 
necrotic-late apoptotic cells [54]. Cells that were Annexin V-FITC positive and 7-AAD negative 
were identified as early apoptotic. Cells that were Annexin V-FITC positive and 7-AAD positive 
were identified as cells in late apoptosis or necrotic. 
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U87MG cells after treatment: calcium retention capacity measurement 
 
The Ca
2+
 retention capacity (CRC) was determined as previously described [55] using Calcium 
Green-5N (λex= 505 nm, λem= 535 nm), a low affinity membrane-impermeant probe that increases 
its fluorescence emission upon Ca
2+
 binding. U87MG cells were suspended in CRC buffer (250 mM 
sucrose, 1 mM Pi-Tris, and 10 mM MOPS-Tris, pH 7.4) and permeabilized by digitonin (40 µM) 
for 5 min at 0°C. For assays, permeabilized U87MG cell suspensions (2 x 10
6
 cells) were incubated 
with CRC buffer supplemented with the respiratory substrate 5 mM succinate and 0.25 µM Calcium 
Green-5N; Ca
2+
 pulses were added at 3 min intervals until onset of the permeability transition. To 
evaluate the effect exerted by TSPO ligands on MPT pore, CRC was measured by loading 
digitonin-permeabilized cells with a train of Ca
2+
 pulses, in the presence or in the absence of test 
compounds. All experiments were performed at 25 °C. By the use of a kinetic program, 
fluorescence was measured with a microplate fluorimeter equipped with thermostatic control (Victor 
Wallac 2, Perkin Elmer, CA, USA). 
 
Statistical analyses 
 
The nonlinear multipurpose curve-fitting program, GraphPad Prism (version 3.0; GraphPad 
Software Inc., San Diego, CA), was used for data analysis and graphic presentations. All data are 
presented as the means ± SEM. Statistical analysis was performed by one-way analysis of variance 
(ANOVA) with Bonferroni’s corrected t-test for post-hoc pair-wise comparisons. P<0.05 was 
considered statistically significant. 
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Results 
 
Quantification of TSPO binding sites in human U87MG cells 
 
The U87MG cell line was chosen as in vitro cancer model. Previous literature data have 
demonstrated that this cell line expresses TSPO, but TSPO levels have never been quantified [56]. 
In the present work, TSPO levels were measured in U87MG cells by radioligand binding assays 
using the high affinity TSPO radioligand [
3
H]PK11195, as described in several cellular systems [43, 
57]. TSPO density was quantified in terms of maximum specific binding of [
3
H]PK11195 in 
membrane homogenate obtained by U87MG cells. The [
3
H]PK11195 specific binding reached 
saturation and the Scatchard analysis of saturation data yielded a single straight-line plot indicating 
the presence of a homogenous population of high affinity binding sites (Kd = 4.2±0.4 nM). The 
value of maximum number of binding sites (Bmax) was 3340 ± 40 fmol/mg protein (Fig. 1B). As 
described in methods section, the Bmax value was used to calculate the irDE-MPIGA dose useful to 
saturate TSPO binding sites during U87MG cell treatments. 
 
irDE-MPIGA interacts stably with TSPO during U87MG cell treatment 
 
To determine whether the irDE-MPIGA stably interacted with TSPO following cell treatment, 
radioligand binding assays were performed on membrane homogenates obtained from U87MG cells 
treated with TSPO saturating irDE-MPIGA concentration. Specifically, [
3
H]PK11195 binding assay 
was explored in U87MG cell membrane homogenates after 1.5 h cell treatment (time required for a 
covalent irDE-MPIGA-TSPO interaction [39]) and 24 h cell treatment. After cell treatments, it 
would be expected that [
3
H]PK11195 did not bind to TSPO binding sites, as they should be already 
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occupied by irDE-MPIGA. This was observed in 1.5 h irDE-MPIGA-treated U87MG cell 
membrane homogenates (Fig. 2A). In 24 h irDE-MPIGA-treated sample, only a partial abolition of 
the [
3
H]PK11195 bond was evidenced, suggesting that only a portion of TSPO binding sites (about 
40 %) was stably occupied by irDE-MPIGA (Fig. 2A). We hypothesized that the cell treatment with 
irDE-MPIGA stimulated the de novo synthesis of TSPO molecules, which remained “irDE-
MPIGA-free” due to unavailability of compound in culture medium. In support of this thesis, real-
time RT-PCR analysis showed that TSPO mRNA levels increased after irDE-MPIGA treatment for 
6 and 12 h (Fig. 2B). In an attempt to evaluate whether the increase of mRNA corresponded to 
increased TSPO protein levels, Western blotting analysis was performed. Using an antibody 
directed to human TSPO full length amino acid sequence, the blotting showed a band corresponding 
to 54 kDa molecular weight (Fig. 2C). This band indicated the presence of TSPO polymers, as 
previously described [58, 59]. Such polymers are formed by covalent binding between TSPO 
monomers at the carboxyl terminal [59]. The present results show that TSPO polymers are already 
evident in control U87MG cells and increase in 24 h irDE-MPIGA-treated U87MG cells with 
respect to control sample (Fig. 2C). 
 
irDE-MPIGA inhibits U87MG cell viability 
 
The effect exerted by irDE-MPIGA (as nanomolar single dose) on U87MG cell viability was 
monitored over the time. The results showed a significant time-dependent reduction of viable 
U87MG cells after 6 and 24 h of treatment (Fig. 3A). The percentage of dead cells resulted 
significantly increased in 6h irDE-MPIGA-treated cell sample. In parallel, the effect of the 
reversible TSPO ligand PIGA on U87MG cell viability was investigated. In order to establish the 
PIGA dose for cell viability assays, the compound concentration able to inhibit 50% of U87MG cell 
viability (IC50 value) was determined after 24 h treatment. PIGA induced a dose-dependent 
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inhibition of U87MG cell viability with an IC50 value of 2.5±0.5 µM (data not shown). The U87MG 
cell treatment with PIGA at IC50 dose at various times did not show a significant reduction of cell 
viability before 24 h treatment (Fig. 3B). 
In order to assess the specific irDE-MPIGA efficacy to induce death in U87MG cells, we evaluated 
its effect on cell viability in TSPO silenced cells in comparison with scramble (negative control). As 
first step, to quantify the TSPO siRNA efficacy to reduce TSPO expression levels, radioligand 
binding assays were performed. The specific [
3
H]PK11195 binding to U87MG cell membranes, 
prepared from negative control and TSPO siRNA cells, was measured at 48 and 72 h from 
transfection. As showed in Figure 4A, 48 and 72 h after transfection the specific [
3
H]PK 11195 
binding was reduced of 32% and 40% in cells transfected with TSPO siRNA, respectively. Cell 
viability assays showed that the susceptibility of 48 h and 72 h TSPO siRNA transfected cells to the 
death-inducting effect of irDE-MPIGA was significantly reduced in comparison to those shown by 
negative control (Fig. 4B). This difference resulted greater in magnitude in 72 h TSPO silenced 
sample (Fig. 4B).  
 
Nanomolar dose of irDE-MPIGA does not inhibit ATP synthase activity 
 
We evaluated whether the dose of TSPO ligands used for U87MG cell treatments was able to affect 
ATP synthase activity. To this aim, ATP synthase was solubilized from U87MG cells and the ATP 
hydrolysis relative specific activity was measured in the absence and in the presence of nanomolar 
irDE-MPIGA (25 nM) or micromolar PIGA (2.5 mM) or the classic TSPO ligand PK11195 used as 
reference compound at 2.5 mM and 250 mM. This last concentration was chosen to verify the 
response of the enzyme to the TSPO ligand, as previously described in literature [60]. The 
measurement of the relative ATP hydrolysis specific activity revealed that irDE-MPIGA, PIGA and 
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2.5 mM PK11195 did not significantly affect ATP synthase activity (Fig. 4C). In the presence of 
250 mM PK11195, the relative ATP hydrolysis specific activity was 43% with respect to control 
sample (Fig. 4C). This result was in agreement with the data reported by Cleary and coworkers 
[60]. 
 
irDE-MPIGA does not block cell cycle in U87MG cells 
 
In order to monitor whether the observed cell viability reduction was due to inhibition of cell cycle 
progression, cell cycle analysis was performed after U87MG cell treatments with irDE-MPIGA 
nanomolar dose (1.25 x 10
-3
 nmol/1x10
6
 cells). Results showed comparable G1, S and G2/M phases 
in irDE-MPIGA-treated and DMSO-treated cells (Fig. 5B), suggesting that the TSPO ligand did not 
block cell cycle in U87MG cells. Similar results were obtained in samples treated with micromolar 
dose (2.5 mM) of the reversible TSPO ligand PIGA (Fig. 5C). 
 
irDE-MPIGA induces effectively apoptosis in U87MG cells 
 
To investigate whether irDE-MPIGA induced apoptosis, dissipation of ΔΨm and externalization of 
phosphatidylserine were evaluated on irDE-MPIGA-treated U87MG cells. Specifically, to monitor 
ΔΨm changes flow cytometry analysis using JC-1 on irDE-MPIGA-treated U87MG cells following 
various incubation times was performed. Representative examples of the flow cytometry analysis 
are shown in Fig. 6A. The majority of control DMSO-treated cells (99%; control sample) showed 
high fluorescence emission in both channels and were found in the upper right (UR) quadrant of the 
plot. The remaining DMSO-treated cells (1 %) showed low fluorescence emission in FL2 and 
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therefore were found in the lower right (LR) quadrant. Upon irDE-MPIGA treatment, an increase 
was observed in the percentage of the U87MG cells plotting in the LR quadrant, consistent with 
ΔΨm dissipation. In particular, significant changes in ΔΨm were observed after treatment for 3 and 
6 h, but not at 12 and 24 h (Fig. 6B). The results obtained by similar experiments performed using a 
micromolar dose of the reversible TSPO ligand PIGA revealed significant ΔΨm change at 12 and 
24 h (Fig 6C).  
To monitor externalization of phosphatidylserine flow cytometric analysis using Annexin V/7-AAD 
dual staining was performed (Fig. 7). Annexin V positive and 7-AAD negative U87MG cells were 
detected, which indicate cells in the early phase of apoptosis, in samples treated with irDE-MPIGA 
for 6 h (Fig. 7B). Similar results were obtained in samples treated with the reversible TSPO ligand 
PIGA for 24 h (Fig. 7C).  
 
irDE-MPIGA modulates mitochondrial permeability transition pore in U87MG cells 
 
The ability of irDE-MPIGA to induce mitochondrial permeability transition (MPT) was tested with 
the sensitive Ca
2+
 retention capacity (CRC) assay, a sensitive measure of the propensity of MPT 
pore to open. The CRC is a quantitative MPT assay that measures the amount of Ca
2+
 that 
mitochondria can retain before the release of sequestered Ca
2+ 
by induction of MPT. “MPT-
inhibitors” and “MPT-inducers” are compounds that increase and decrease the amount of Ca
2+
 
required to induce MPT, respectively [61]. Specifically, following treatment of U87MG cells with 
digitonin, CRC was measured by loading cells with a train of Ca
2+
 pulses, in the presence or in the 
absence of test compounds, until the fast Ca
2+
 release occurred, marking the MPT onset. Control 
U87MG cells readily took up Ca
2+
 pulses (Fig. 8A) in a process that was sensitive to the uncoupling 
agent CCCP, suggesting that the Ca
2+
 was loaded specifically into mitochondria (Fig. 8A). In 
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addition, we examined whether CRC was affected by the cyclosporin A (CsA), a well-known 
inhibitor of MPT pore opening. The results showed that CsA increased CRC, suggesting the drug 
ability to desensitize the MPT pore to Ca
2+
 in U87MG cells (Fig. 8A). We next tested the effect of 
TSPO ligands on the CRC. Two typologies of results were obtained depending on the time 
exposure of U87MG cells with irDE-MPIGA. CRC assay is usually performed with short-time drug 
exposure (a few minute) before or simultaneously to Ca
2+
 loading. In this experimental setting, 
irDE-MPIGA interaction with TSPO is still reversible. Therefore, we decided to perform CRC 
assay both simultaneously to Ca
2+
 loading and after 2 h exposure with irDE-MPIGA before Ca
2+
 
loading, which is the time required for the formation of covalent binding [39]. Interestingly, when 
the irDE-MPIGA low nanomolar dose was simultaneously added to Ca
2+
 loading in cell suspension, 
the CRC was increased with respect to control sample, indicating that irDE-MPIGA was able to 
desensitize mitochondria to Ca
2+
-induced MPT (Fig. 8B). An opposite result was obtained when a 
low nanomolar dose of irDE-MPIGA was added 2 h before the Ca
2+
 loading. In this experimental 
condition, the CRC was lowered with respect to control sample, indicating that irDE-MPIGA was 
able to sensitize mitochondria to Ca
2+
-induced MPT (Fig. 8C). This ligand-mediated effect on CRC 
was CsA-sensitive (data not shown). The reversible TSPO ligand PIGA, added at micromolar dose 
simultaneously to Ca
2+
 loading, lowered CRC with respect to control sample (Fig. 8B). 
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Discussion 
 
In the present work, the most relevant result concerns the demonstration that several dynamic 
events occurred in human glioblastoma multiforme U87MG cells following the treatment with the 
irreversible TSPO ligand irDE-MPIGA. 
The irDE-MPIGA ligand is structurally related to 2-phenylindol-3-ylglyoxylamide specific TSPO 
ligands developed by our group [40], and it has been previously investigated in detail, 
demonstrating the irreversible covalent nature of its interaction with the target protein [39]. A 
number of irreversible TSPO ligands have been previously employed to improve the understanding 
of TSPO structure and ligand binding sites [62-66]. However, to the best of our knowledge, this is 
the first study in which an irreversible ligand was used to investigate a functional activity of TSPO. 
After irDE-MPIGA U87MG cell exposure for 3-6 h, a period of time in which the irreversible 
binding occurred, a TSPO saturating nanomolar dose (1.25 x 10
-3
 nmol/1x10
6
 cells) was able to 
induce ΔΨm collapse and externalization of phosphatidylserine, all events characteristic of early 
apoptotic stages [67,68]. The same cellular responses were evidenced using the reversible TSPO 
ligand PIGA too, but only at micromolar concentration (2.5 mM) and following 12 h cell exposure. 
Other TSPO reversible ligands have been reported to exert the same effect at micromolar ligand 
concentration [17-30]. Both irDE-MPIGA and PIGA were effective to halve the number of viable 
U87MG cells after 24 h cell treatment at nanomolar and micromolar concentration, respectively. 
The results highlighted that a stable ligand-target interaction is essential to improve the efficacy of 
the ligands, as emerged in the recent papers, in which a correlation between the residence time and 
a potentiation of the pharmacological effects has been demonstrated [69-70]. The present results 
challenge to explore in the future the binding kinetic parameters of the reversible TSPO ligands and 
to investigate cellular responses triggered by ligands with different residence times.  
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It is important to underline that the effects elicited by the irreversible ligand were obtained after a 
single nanomolar compound administration up to 24 h cell treatment. On the other hand, data 
obtained after l2-24 h cell treatment showed a restoration of cell survival parameters in U87MG 
cells, as shown by the disappearance of ΔΨm collapse and the reduction of dead cell number with 
respect to control. Actually, a TSPO new synthesis was demonstrated and this event could take into 
account, at least in part, of the restoration of cell survival which could be due to a compensatory cell 
mechanism [71]. On the other hand, ligand-TSPO interaction could activate other mechanisms, such 
as neurosteroid new synthesis, thus determining cellular responses able to reverse the death signals. 
Studies are in progress to explore this issue in a standardized experimental setting. Noteworthy, 
several conflicting literature data have been reported for TSPO ligands, which could be arisen from 
troubles in comparing results from different cellular/subcellular settings [36].  
Highly debated data in TSPO literature regards the ability of TSPO ligands to modulate MPT pore 
[72-80]. In the present work, the TSPO ligand modulatory activity on MTP pore functioning was 
investigated on U87MG cell suspension with digitonin-permeabilized plasmatic membrane at 
different times. Notably, using nanomolar irDE-MPIGA before the instauration of TSPO 
irreversible binding (< 90 min cell treatment time), the ligand caused a major resistance to Ca
2+
-
induced MPT pore opening, a phenomenon that generally causes a protection against cell death. 
Accordingly, the reversible TSPO ligand PIGA at nanomolar concentration was able to induce cell 
proliferation in serum-free cell culture conditions (data not shown). In line with this finding, a 
protection against cell death has been previously demonstrated by nanomolar dose of TSPO ligands 
such as Ro5-4864 (at 30 nM), diazepam (at 47 nM), and flunitrazepam (at 207 nM) [14]; PK11195 
and Ro5-4864 (at 10 nM) [15]; SSR180575 and Ro5-4864 (at 100 nM) [16]. On the contrary, 
following 2 h irDE-MPIGA cell treatment (a time necessary to form TSPO-ligand covalent 
binding), a nanomolar ligand concentration favored Ca
2+
-induced MPT pore opening. The same 
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effect was evidenced using PIGA at micromolar concentration (2.5 mM), accordingly to data 
obtained using other TSPO reversible ligands [72-74].  
The lack of correlation between TSPO ligand binding affinity and in vitro efficacy is another of the 
most recurrently questioned issue. In other drug-target systems, the drug dose causing a functional 
effect is usually about 100 times the drug binding affinity to its target (expressed in terms of Kd). In 
the case of the ligand-TSPO system, the efficacy dose of a TSPO ligand is up to 1,000-100,000 
times its Kd values [17-30, 32-36].  
For this reason, it has been suggested that other targets may be involved in determining the cellular 
activities. ATP synthase (a recently suggested structural MPT pore component [81]) has been 
proposed as an additional target candidate for TSPO ligands [60, 82]. Actually, irDE-MPIGA and 
PIGA at nanomolar (25 nM) and low-micromolar (2.5 mM) concentrations, respectively, did not 
affect ATP synthase functionality. No effect was shown by the classic TSPO ligand PK11195     
(2.5 mM) too, according to literature data [60].  
In order to verify the specific effect of TSPO ligand irDE-MPIGA siRNA technique was used to 
silence TSPO expression. The reduction of TSPO levels obtained by genetic manipulation protected 
against the death-inducing activity of irDE-MPIGA, thus indicating the specific role of TSPO in 
mediating this effect.  
In conclusion, in the complex scenario of TSPO generated by conflicting pharmacological data, the 
irreversible ligand irDE-MPIGA has allowed to monitor the occupancy of TSPO sites in a 
standardized cellular system and to obtain valuable effects at nanomolar concentration (strictly 
correlated with its binding affinity), differently from the reversible ligand PIGA. The effects were 
demonstrated to be related to TSPO occupancy. 
Thus, irDE-MPIGA emerges as a useful tool to obtain important information about cellular 
activities generated by the specific interaction with TSPO in U87MG cells. The obtained results 
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confirmed that the pharmacological profiles of drugs depend on their concentrations and 
demonstrated a correlation between the ligand effective dose and the residence time. 
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Legends 
 
Fig. 1 A) Chemical structure of irDE-MPIGA and schematic representation of its interaction with 
TSPO. B) Representative saturation curve and Scatchard plot (inset) of the specific [
3
H]PK11195 
binding to U87MG cell membranes. U87MG cell membranes were incubated with increasing 
concentrations of [
3
H]PK11195 for 90 min at 0 °C. Non-specific binding was determined in the 
presence of 1 µM PK11195. Data are from a single experiment carried out in triplicate. The Kd and 
Bmax values were 4.2 ± 0.4 nM and 3340 ± 40 fmol/mg protein, respectively. Three such 
experiments yielded similar results. 
 
Fig. 2 U87MG cell treatments with a TSPO saturating nanomolar dose of irDE-MPIGA. A) stable 
interaction between irDE-MPIGA and TSPO binding sites: 1.5 or 24 h irDE-MPIGA- (1.25 x 10
-3
 
nmol/1x10
6
 cells) or DMSO-treated U87MG cells were used to prepare cell membrane 
homogenates and perform [
3
H]PK11195 radioligand binding assays. [
3
H]PK11195 binding was 
calculated as fmol/mg of protein and showed as percentage with respect to control. Data are from 
two experiments carried out in triplicate. A complete inhibition of [
3
H]PK11195 binding was 
evidenced in 1.5 h irDE-MPIGA-treated U87MG cell membrane homogenates with respect to 
control sample (p<0.001). A statistical significant reduction of [
3
H]PK11195 binding was evidenced 
in 24 h irDE-MPIGA-treated U87MG cell membrane homogenates with respect to control sample 
(p<0.01). B) irDE-MPIGA treatment increased TSPO mRNA levels: irDE-MPIGA- (1.25 x 10
-3
 
nmol/1x10
6
 cells) or DMSO-treated U87MG cells for the indicated times were used to perform the 
relative quantification of TSPO mRNA by real-time RT-PCR. TSPO mRNA levels significantly 
increased at 6 (p<0.01) and 12 h (p<0.001) of cell treatment. C) irDE-MPIGA treatment increased 
TSPO polymer levels: 24 h irDE-MPIGA- (1.25 x 10
-3
 nmol/1x10
6
 cells) or DMSO-treated U87MG 
cells were used to perform the relative quantification of TSPO protein by Western blot. 
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Representative Western blotting chart is presented. TSPO primary polyclonal antibody (FL-169, 
Santa Cruz Biotechnology) recognizes proteins of approximately 54 kDa in DMSO- and irDE-
MPIGA-treated cells, corresponding to TSPO polymers. TSPO polymer levels significantly 
increased at 24 h of cell treatment (p<0.01). 
 
Fig. 3 irDE-MPIGA inhibits viability of U87MG cells. A) irDE-MPIGA effect on U87MG cell 
viability. U87MG cells were treated with irDE-MPIGA nanomolar dose (1.25 x 10
-3
 nmol/1x10
6
 
cells) or DMSO for indicated times. The graph shows the number of viable and dead cells (mean 
values ±SEM). A significant reduction of viable and U87MG cells was evidenced in 6 (p<0.01) and 
24 h (p<0.001) irDE-MPIGA-treated sample. A significant increase of cell death were evidenced in 
6 h irDE-PIGA-treated sample (p<0.01). B) U87MG cells were treated with a micromolar dose of 
the reversible TSPO ligand PIGA (2.5 µM) or DMSO for indicated times. A reduction in U87MG 
cell viability (p<0.001) and an increase of cell death (p<0.001) were evidenced in 24 h PIGA-
treated sample. Bars represent the means of three independent experiments performed in triplicate. 
 
Fig.4 TSPO silencing protects U87MG cells against irDE-MPIGA-induced cell death; and irDE-
MPIGA doesn’t affect functionality of ATP synthase. A) Assessment of TSPO silencing in U87MG 
cells by radioligand binding assays. The specific [
3
H]PK11195 binding to scramble (negative 
control) and TSPO siRNA U87MG cell membranes were determined. The results are expressed as 
percentage of the specific [
3
H]PK11195 binding measured in TSPO siRNA vs negative control cells 
at which the arbitrary value of 100% was attributed. Data are obtained from at least three 
independent experiments, done in duplicate. Each bar represents the mean value ± SEM. The 
[
3
H]PK11195 binding in TSPO silenced cells was significantly reduced 48 h and 72 h after 
transfection (***p<0.001). B) Effect of TSPO silencing on U87MG cell death induction by irDE-
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
36 
 
MPIGA. U87MG cells transfected with TSPO siRNA or scramble (negative control) for 48 and 72 h 
were treated with DMSO or a nanomolar dose of irDE-MPIGA (1.25 x 10
-3
 nmol/1x10
6
 cells) for 6 
h and then the viable and dead cells were determined by Trypan blue dye exclusion assay. For each 
sample, the dead cells were expressed as percentage versus total cells. The cell death in the irDE-
MPIGA-treated cells are scaled in respect to their DMSO controls. In transfected U87MG cells 
expressing normal TSPO levels (scramble samples), irDE-MPIGA increased cell death 
approximately 2-fold compared to baseline level (Ctrl-DMSO). In transfected U87MG cells 
expressing reduced TSPO levels (TSPO siRNA samples), the cell death-inducing effect of irDE-
MPIGA was significantly reduced. The results are shown as mean ± SEM, derived from three 
independent experiment, done in duplicate. *p<0.05; **p<0.01. C) irDE-MPIGA effect on ATP 
synthase functionality. ATP synthase was solubilized from U87MG cells and the ATP hydrolysis 
relative specific activity was measured as described in methods section. To evaluate if TSPO ligand 
affected ATP synthase activity, the relative ATP synthase specific activity was compared between 
TSPO ligand-treated and control sample. The results showed that both irDE-MPIGA (25 nM) and 
PIGA (2.5 mM) did not significantly affect ATP synthase activity. The graph shows also the result 
obtained by the classic TSPO ligand PK11195 (250 mM) that was used as reference TSPO 
compound (p<0.05). 
 
Fig.5 irDE-MPIGA did not block U87MG cell cycle. The percentage of U87MG cell cycle phases 
was measured after irDE-MPIGA treatment (1.25 x 10
-3
 nmol/1x10
6
 cells) for 24 h. A) 
Representative dot plots of cell population profile and DNA content are shown. Histograms 
represent the results obtained with the Muse™ Cell Cycle software module: they show that the 
percentage of U87MG cells in each population did not differ between irDE-MPIGA-treated and 
control cells (B) and between micromolar PIGA-treated (2.5 mM) and control cells (C). 
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Fig. 6 nanomolar irDE-MPIGA induces ΔΨm dissipation in U87MG cells. U87MG cells were 
treated with nanomolar irDE-MPIGA (1.25 x 10
-3
 nmol/1x10
6
 cells) or micromolar PIGA (2.5 mM) 
for indicated times. A) Representative dot plots of DMSO-treated, or irDE-MPIGA-treated U87MG 
cells (CCCP is the positive control): after cell treatment with irDE-MPIGA, mitochondrial 
depolarization is visible by a fluorescence decrease in the FL-2 channel and an increase in FL-1 
channel. B) Time-course analysis of ΔΨm in irDE-MPIGA-treated U87MG cells is represented. 
Histograms show the mean values of U87MG cell percentages either in the UR (polarized 
mitochondria) or LR (depolarized mitochondria) quadrant of the ΔΨm analysis plots, derived from 
three independent experiments. Following U87MG cell exposure to irDE-MPIGA for different 
periods of time, a progressive time-dependent changes of ΔΨm values was revealed, indicating that 
irDE-MPIGA was able to induce ΔΨm dissipation in U87MG cells (p<0.001). C) Time-course 
analysis of ΔΨm in PIGA-treated U87MG cells is represented. PIGA induced ΔΨm dissipation after 
12 (p<0.05) and 24 h (p<0.001). Data derived from three experiments conducted in duplicate. 
 
Fig. 7 nanomolar irDE-MPIGA induces externalization of phosphatidylserine in U87MG cells. 
U87MG cells were treated with irDE-MPIGA (1.25 x 10
-3
 nmol/1x10
6
 cells) for indicated times. 
Harvested cells were stained with annexin V/7-AAD and analyzed by flow cytometry. A) 
Representative dot plots: the lower left quadrant shows the viable cells, the upper left quadrant 
shows cell debris, the lower right quadrant shows the early apoptotic cells and the upper right 
quadrant shows the late apoptotic and necrotic cells. The bar graph shows a significant increase of 
cells in the early phase of apoptosis after 6 h of nanomolar irDE-MPIGA treatment (p<0.001) (B) 
and after 24 of 2.5 mM PIGA treatment (p<0.001) (C). L= live; EA= early apoptosis; LA= late 
apoptosis; D= dead.  
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Fig. 8 nanomolar irDE-MPIGA affects MPT pore activity in U87MG cells. The U87MG cells were 
suspended with CRC medium and permeabilized with digitonin. To the CRC-suspended, 
permeabilized-cells were added 0.25 µM Calcium Green-5N, 5 mM succinate and a train of Ca
2+
 
pulses. A) Representative traces of U87MG cell treatment with 1 mM CsA or 5 mM CCCP are 
reported in blue and orange, respectively. Trace black is control sample. B) simultaneously to Ca
2+
 
loading, permeabilized-cells were incubated with a low nanomolar dose of irDE-MPIGA (1.25 x   
10
-3
 nmol/1x10
6
 cells) or micromolar dose of PIGA. Representative traces of U87MG cell treatment 
with irDE-MPIGA or PIGA are reported in red and green, respectively. C) In order to reach 
irreversibility of ligand binding to TSPO, permeabilized-cells were incubated for 2 h with a low 
nanomolar dose of irDE-MPIGA (1.25 x 10
-3
 nmol/1x10
6 
cells) before Ca
2+
 loading. Representative 
traces of U87MG cell treatment with irDE-MPIGA is reported in red. Trace black is control sample. 
D) Results were represented as CRC normalized to CRC of control (CRC0). The simultaneous 
addition of irDE-MPIGA and Ca
2+
 loading in cell suspension significantly increased the CRC 
(p<0.01). irDE-MPIGA added 2 h before the Ca
2+
 loading was able to reduce the CRC (p<0.001). 
PIGA, added simultaneously to Ca
2+
 loading, lowered CRC with respect to control sample (p<0.05). 
Data refer to the mean ± SEM of three independent experiments. 
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